The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | IDH1-targeted therapy continues to reshape AML treatment
Agnieszka Wierzbowska, MD, PhD, Medical University of Lodz, Lodz, Poland, discusses the evolving treatment landscape for IDH1-mutated acute myeloid leukemia (AML). She reviews the impact of ivosidenib-based therapy, highlights promising early results from triplet combinations with venetoclax and azacitidine, and explains how ongoing Phase III studies could further redefine the standard of care for patients unfit for intensive chemotherapy. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
